Virchow Medical Raises $4M Seed to Turn Biopsy Waste into Precision Data Assets

A biopsy needle does its job in seconds. What happens after decides everything. Tissue gets pulled, tested, and the remainder fades into irrelevance. No replay. No backup plan. Precision medicine, running on a single take.

Virchow Medical, Inc. looked straight at that blind spot and built where others shrugged. Wasted tissue was not a side effect to them. It was the flaw. So they engineered around it, turning what gets discarded into something that compounds in value.

Now they have $4M in fresh fuel to keep pushing. Seed round. Clean and focused. Led by Cerberus Ventures, with Chenny Zhang stepping into the boardroom. You bring in Cerberus, you are not just raising capital, you are inviting in people who expect outcomes, not excuses.

Respect to Alexander Arrow and Wilfrido Mojica for getting this moving from concept to conviction. Co-founders who saw that the real bottleneck in precision oncology was not always discovery. Sometimes it was preservation. Sometimes the problem is not what you can find, it is what you failed to keep.

Crow’s Nest is not just a clever name, it is perspective. You climb higher, you see more. In this case, it is capturing cellular material that usually gets tossed aside like yesterday’s news. Pair that with Virchow Vault and now you are not just collecting samples, you are building a memory bank for medicine. Tissue that sticks around long enough to matter.

And here is the part people in the cheap seats miss. The round was not just VCs writing checks. Practicing pathologists and interventional radiologists showed up with capital. The same people who live inside the problem decided this was worth backing. That is signal. Real signal.

Early stage, yes. But 6 institutions already running concordance work tells you this is not theory dressed up as ambition. This is product meeting practice, quietly stacking receipts.

The lesson writes itself if you are paying attention. Build where the friction lives. Not where the spotlight is. The market will meet you there, especially when the people closest to the pain start investing alongside you.